Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

BioNTech, Genentech cancel ph. 2 test of personalized cancer vax

28 August 2026 · By · Wire by Fusion42

Published

28 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 28 August 2026 · Fusion42 review

BioNTech and Genentech have stopped a phase 2 trial of their personalized mRNA cancer vaccine for colorectal cancer due to a higher death rate in vaccinated patients compared to controls, while a combination therapy trial continues.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

BioNTech’s setback with their colorectal cancer vaccine as a standalone treatment shows you the risk of pursuing mRNA monotherapies in tough tumor types. You need to rethink survival bets and prioritise combination approaches to stay competitive in cancer immunotherapy.

◆ Coverage

2 sources · 28 Aug 2026

◆ Related on Wire

◆ Topics

Biotechcancer-vaccinemrnafailed-trialsclinical-resultsbiotech